
<?xml version='1.0' encoding='UTF-8'?>
<article>
<front>
<journal-meta>
<journal-id journal-id-type='publisher'>IJRAP</journal-id>
<journal-title>International Journal of Research in Ayurveda and Pharmacy</journal-title>
<issn pub-type='ppub'>2277-4343</issn>
 <publisher>
<publisher-name>Moksha Publishing House </publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type='other'>10.7897/2277-4343.175174</article-id>
<title-group>
<article-title>AI-ASSISTED DRUG DISCOVERY OF WEIGHT MANAGEMENT AGENTS: ORLISTAT, SEMAGLUTIDE, AND NATURAL PRODUCTS GARCINIA CAMBOGIA AND GLUCOMANNAN
</article-title>
</title-group>
<contrib-group>
<contrib contrib-type='author'>
<name>Rasha S. Suliman *</name>
</contrib>
<contrib contrib-type='author'>
<name> Amna A Alalawi</name>
</contrib>
<contrib contrib-type='author'>
<name> Fatima K. Ahmed</name>
</contrib>
<contrib contrib-type='author'>
<name> Shaza M. Osman</name>
</contrib>
<contrib contrib-type='author'>
<name> Hayat Al Hosani</name>
</contrib>
<contrib contrib-type='author'>
<name> Noon Kamil</name>
</contrib>
<contrib contrib-type='author'>
<name> Wong Nee</name>
</contrib>
<contrib contrib-type='author'>
<name> Ayesha Alqasem</name>
</contrib>
<contrib contrib-type='author'>
<name> Sarah Alakshar</name>
</contrib>
<contrib contrib-type='author'>
<name> Manal Buabeid</name>
</contrib>
</contrib-group>
<pub-date>
<month>11</month>
<year>-0001</year>
</pub-date>
<fpage>60</fpage>
<lpage>71</lpage>
<abstract><title>Abstract</title>
Obesity is a major public health issue worldwide and is a major risk factor for type 2 diabetes, cardiovascular diseases, and metabolic syndrome. Obesity management includes pharmacological interventions, natural products, and lifestyle changes. This study comprehensively evaluates two of the most popular anti-obesity drugs, Orlistat and Semaglutide, and the natural products Garcinia cambogia and Glucomannan. Scientific literature suggests that Orlistat is a potent anti-obesity agent that decreases body weight, BMI, and waist circumference by inhibiting gastrointestinal lipases and limiting the absorption of dietary fats. Semaglutide, a glucagon-like peptide-1 receptor agonist, induces weight loss through mechanisms that involve appetite reduction, delayed gastric emptying, and insulin secretion enhancement. Garcinia cambogia, with high hydroxycitric acid content, may inhibit lipogenesis and influence appetite control through central nervous system-mediated neurotransmitter action, whereas Glucomannan, a soluble dietary fiber, may increase feelings of fullness and lower caloric intake through gel formation in the GI tract. In silico pharmacokinetic and pharmacodynamic studies indicated that Orlistat and Glucomannan have good safety profiles; however, the activity of Semaglutide could not be predicted due to its peptide nature. Predictions for biological activity indicated that the natural compounds may have anti-obesity, lipid-lowering, and anti-diabetic activities. Overall, clinical and computational studies demonstrate the relative effectiveness, mechanisms of action, and safety profiles of synthetic drugs and herbal supplements for weight loss. This is especially useful for clinicians, researchers, and individuals seeking evidence-based approaches to managing obesity. Further studies are necessary to assess safety and determine optimal dosage regimens for pharmacological and herbal agents for weight loss.
</abstract>
<kwd-group>
<title>Keywords</title>
<kwd>Obesity</kwd>
<kwd> Orlistat</kwd>
<kwd> Semaglutide</kwd>
<kwd> Garcinia cambogia</kwd>
<kwd> Glucomannan</kwd>
<kwd> In Silico Analysis</kwd>
<kwd> Weight Management</kwd>
<kwd> Pharmacokinetics</kwd>
<kwd> Pharmacodynamics</kwd>
</kwd-group>
<counts><ref-count count='0'/><page-count count='7'/></counts>
</article-meta></front><back><ref-list><title>References</title></ref-list></back></article>
